期刊
JOURNAL OF HEPATOLOGY
卷 51, 期 4, 页码 829-834出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2009.04.019
关键词
Clevudine; Hepatitis B; Adverse effects; Myopathy
资金
- National Research Foundation of Korea [전06A1102] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Clevudine (L-FMAU) is a thymidine L-nucleoside analogue that was recently introduced for the treatment of chronic hepatitis B virus infection. Previous studies showed that clevudine has potent and sustained antiviral activity without causing viral resistance. No severe adverse event occurred during clinical trials. We describe two cases of drug-induced myopathy during long-term treatment of chronic hepatitis B with clevudine. (C) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据